Trials / Terminated
TerminatedNCT04537806
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Sage Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexanolone | Administered as IV infusion. |
| DRUG | Placebo | Administered as IV infusion. |
Timeline
- Start date
- 2020-12-18
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2020-09-03
- Last updated
- 2022-08-19
- Results posted
- 2022-07-27
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04537806. Inclusion in this directory is not an endorsement.